☆ 4.6 Article

Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults

BMJ OPEN (2022)

Related references

Note: Only part of the references are listed.

Editorial Material Medicine, General & Internal

Efficiency decreases

Halane Vaillant-Roussel et al.

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Add to Collection

Review Medicine, General & Internal

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

Daniel R. Feikin et al.

Summary: This study systematically reviewed the duration of protection provided by COVID-19 vaccines against various clinical outcomes. The findings indicate that the effectiveness or efficacy of the vaccines decreased from 1 to 6 months after full vaccination, but remained high against severe disease. Evaluating the effectiveness or efficacy of vaccines beyond 6 months is crucial for updating vaccine policies.

LANCET (2022)

Add to Collection

Editorial Material Infectious Diseases

A promising inactivated whole-virion SARS-CoV-2 vaccine

Irina Isakova-Sivak et al.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemical Research Methods

Evaluation of a surrogate virus neutralization test for high-throughput serosurveillance of SARS-CoV-2

Joachim Marien et al.

Summary: An independent evaluation of a commercially available surrogate virus neutralization test (sVNT) showed high sensitivity in detecting neutralizing antibodies against SARS-CoV-2, making it a powerful tool for monitoring neutralizing antibodies in cohort and population studies, especially in regions lacking infrastructure for traditional neutralization tests.

JOURNAL OF VIROLOGICAL METHODS (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Review Multidisciplinary Sciences

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Victoria Rotshild et al.

Summary: New COVID-19 vaccines from Pfizer and Moderna showed the highest efficacy in preventing symptomatic COVID-19 in adults. There was no significant difference in the prevention of symptomatic disease among the elderly population. mRNA-1273 and Gam-COVID-Vac vaccines were associated with a higher probability of protection against severe COVID-19 compared to other vaccines.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Infectious Diseases

Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis

Qiao Liu et al.

Summary: This study included 58 studies, with the effectiveness of a single dose vaccine in preventing SARS-CoV-2 infections at 41% and two doses reaching 85% effectiveness. The vaccines are generally safe and help reduce the incidence of COVID-19-related deaths and severe cases.

INFECTIOUS DISEASES OF POVERTY (2021)

Add to Collection

Review Immunology

Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

Nadim Sharif et al.

Summary: This study conducted a meta-analysis on the efficacy of COVID-19 vaccines, revealing that mRNA vaccines and adenovirus vector vaccines can provide moderate to high protection against COVID-19 in individuals aged 18 and above. However, evidence on the long-term protection of these vaccines in individuals under 16 years old against multiple variants of COVID-19 is limited.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Letter Medicine, General & Internal

COVID-19 battle during the toughest sanctions against Iran

Amirhossein Takian et al.

LANCET (2020)

Add to Collection

Article Immunology

Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Ger Rijkers et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Immunology

Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)

Benjamin Meyer et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Infectious Diseases

SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study

Hossein Poustchi et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Review Medicine, General & Internal

Iran in transition

Goodarz Danaei et al.

LANCET (2019)

Add to Collection

Review Public, Environmental & Occupational Health

Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

Nikolai Petrovsky

DRUG SAFETY (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.